Developer docs
API playgroundTry for free, no card

Search company profiles

Mylan

Full company profile

uuid0008zu5

Namestring
Mylan
Legal namestring
Mylan N.V.
Websiteurl
mylan.in
Company typeenum
Private
Founded yearint
1961
Descriptiontext

Mylan N.V. was a global generic and specialty pharmaceutical company founded in 1961 and headquartered in the Netherlands, with its largest operating base in Hyderabad, India. From inception through 2020, the company built a portfolio spanning oral solid doses, sterile injectables, complex generics, biosimilars, and active pharmaceutical ingredients, manufacturing across 26 global facilities with combined annual dose capacity exceeding 80 billion units and a product portfolio of 1,400+ medicines spanning oncology, immunology, chronic disease, and acute care therapeutic areas. Core technical capabilities centered on complex generics manufacturing, biosimilar development (including G-CSF biosimilars), and generic injectable production, supported by R&D centers in Hyderabad (APIs and OSDs) and Bangalore (injectables).

On November 16, 2020, Mylan N.V. combined with Pfizer's Upjohn unit through an all-stock transaction valued at approximately $40 billion to form Viatris Inc., at which point Mylan N.V. was delisted from NASDAQ and became a wholly-owned subsidiary. The combined entity operates in 165+ countries through a hybrid go-to-market combining direct commercial operations in major markets, hospital and retail pharmacy distribution channels, and government/public health system contracts. Mylan's revenue streams historically comprised commodity generic pharmaceuticals, higher-margin complex generics and biosimilars, and branded established medicines inherited from Upjohn; standalone Mylan revenue is no longer separately disclosed within Viatris consolidated reporting.

Short descriptiontext

Mylan N.V., founded in 1961, was a global generic and specialty pharmaceutical company that became part of Viatris Inc. in 2020 after merging with Pfizer's Upjohn. It serves healthcare systems, hospitals, and retail pharmacies across 165+ countries with 1,400+ medicines.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, biosimilar manufacturing, oral solid dosage, injectable medicines, active pharmaceutical ingredients
Industry3 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAC
Sterile Injectable Generics
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Pharmaceuticals
TypeOne Time License
Description

Revenue from selling generic pharmaceutical products including oral solid doses and injectable medicines across global markets

ad-hoc-news.de
2Complex Generics and Biosimilars
TypeOne Time License
Description

Revenue from complex generic drugs and biosimilars which command higher margins than simple generics, driven by patent expirations of major biologics

biospace.com
3Branded Established Medicines
TypeSubscription Recurring
Description

Revenue from branded established medicines following the merger with Pfizer's Upjohn unit

viatris.in
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mylan N.V. developed, manufactured, and distributed a broad portfolio of generic, complex generic, specialty, and biosimilar pharmaceutical products. Following the 2020 combination with Pfizer's Upjohn unit, the Mylan business now operates as part of Viatris Inc., producing oral solid doses, injectables, APIs, and biosimilars across therapeutic areas such as oncology, immunology, diabetes, and chronic disease, with global manufacturing and R&D operations centered in India (Hyderabad and Bangalore).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • One of the largest global generic pharmaceutical companies with top-tier market position
+1 more record
Product overview1 text field

Mylan N.V., now part of Viatris Inc. following the 2020 merger with Pfizer's Upjohn unit, operates as a global generics, complex generics, and biosimilars company. The company provides a wide range of pharmaceutical products across therapeutic areas including zoledronic acid for bone conditions, herpes treatments, G-CSF biosimilars for neutropenia, docusate sodium, transdermal scopolamine, sucralfate API, dalteparin sodium injection, OTC drugs, plaque psoriasis treatments, and acne medicines. Mylan/Viatris operates manufacturing facilities in India producing oral solid doses and injectables, with R&D centers in Hyderabad and Bangalore. The company operates across 165+ countries with approximately 1,400 medicines.

Product and service11 records
1Zoledronic Acid
CategoryGeneric Pharmaceutical
2Herpes Treatment Drugs
CategoryGeneric Pharmaceutical
3G-CSF and G-CSF Biosimilars
CategoryBiosimilar
4Docusate Sodium
CategoryGeneric Pharmaceutical
5Transdermal Scopolamine
CategoryGeneric Pharmaceutical
6Sucralfate API
CategoryActive Pharmaceutical Ingredient
7Dalteparin Sodium Injection
CategoryGeneric Pharmaceutical
8Over The Counter (OTC) Drugs
CategoryOTC Pharmaceutical
9Plaque Psoriasis Treatment
CategoryGeneric Pharmaceutical
10Acne Medicine
CategoryGeneric Pharmaceutical
11Neurogenic Bladder Infections Treatment
CategoryGeneric Pharmaceutical
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-30
Description

Mankind Pharma received a royalty-free, non-exclusive U.S. license to market a generic version of YUPELRI starting April 23, 2039, as part of settlement resolving Hatch-Waxman patent litigation.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

Mylan Inc. (Viatris) sold its minority stake in Biocon Biologics Ltd to Biocon Ltd for $200 million cash as part of a $400 million two-part transaction, completing the buyback and enabling full integration of Biocon Biologics.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-11-16
Description

Mylan N.V. and Pfizer Inc. completed a global transaction combining Mylan with Upjohn (Pfizer's off-patent branded and generic established medicines business) to create Viatris Inc., forming one of the largest global pharmaceutical companies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Natco/Mylan partnership for GLP-1 drug development in India's weight loss and diabetes-management market competing against branded products.

Strategic tierMinorTypeOthers
Description

Pharmaceutical companies including Mylan sought government price increase for chemotherapy drugs Cisplatin and Carboplatin citing rising raw material costs linked to conflict in West Asia.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A10 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mylan

Generic Pharmaceuticalsmylan.in

Mylan N.V., founded in 1961, was a global generic and specialty pharmaceutical company that became part of Viatris Inc. in 2020 after merging with Pfizer's Upjohn. It serves healthcare systems, hospitals, and retail pharmacies across 165+ countries with 1,400+ medicines.

What Mylan does

Mylan N.V. was a global generic and specialty pharmaceutical company founded in 1961 and headquartered in the Netherlands, with its largest operating base in Hyderabad, India. From inception through 2020, the company built a portfolio spanning oral solid doses, sterile injectables, complex generics, biosimilars, and active pharmaceutical ingredients, manufacturing across 26 global facilities with combined annual dose capacity exceeding 80 billion units and a product portfolio of 1,400+ medicines spanning oncology, immunology, chronic disease, and acute care therapeutic areas. Core technical capabilities centered on complex generics manufacturing, biosimilar development (including G-CSF biosimilars), and generic injectable production, supported by R&D centers in Hyderabad (APIs and OSDs) and Bangalore (injectables).

On November 16, 2020, Mylan N.V. combined with Pfizer's Upjohn unit through an all-stock transaction valued at approximately $40 billion to form Viatris Inc., at which point Mylan N.V. was delisted from NASDAQ and became a wholly-owned subsidiary. The combined entity operates in 165+ countries through a hybrid go-to-market combining direct commercial operations in major markets, hospital and retail pharmacy distribution channels, and government/public health system contracts. Mylan's revenue streams historically comprised commodity generic pharmaceuticals, higher-margin complex generics and biosimilars, and branded established medicines inherited from Upjohn; standalone Mylan revenue is no longer separately disclosed within Viatris consolidated reporting.

Mylan firmographics

Firmographics
Name
Mylan
Legal name
Mylan N.V.
Website
https://mylan.in
Company type
Private
Founded year
1961
Operating status
Acquired
Headcount range
10,001+ employees
Short description
Mylan N.V., founded in 1961, was a global generic and specialty pharmaceutical company that became part of Viatris Inc. in 2020 after merging with Pfizer's Upjohn. It serves healthcare systems, hospitals, and retail pharmacies across 165+ countries with 1,400+ medicines.
Ownership category
akta.pro rank

Mylan industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAC
Sterile Injectable Generics
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Generic pharmaceuticals
  • Biosimilar manufacturing
  • Oral solid dosage
  • Injectable medicines
  • Active pharmaceutical ingredients

Where Mylan is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Mylan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Generic Pharmaceuticals: Revenue from selling generic pharmaceutical products including oral solid doses and injectable medicines across global markets
  2. Complex Generics and Biosimilars: Revenue from complex generic drugs and biosimilars which command higher margins than simple generics, driven by patent expirations of major biologics
  3. Branded Established Medicines: Revenue from branded established medicines following the merger with Pfizer's Upjohn unit

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Mylan product offering

Product offering

Core offering

Mylan N.V. developed, manufactured, and distributed a broad portfolio of generic, complex generic, specialty, and biosimilar pharmaceutical products. Following the 2020 combination with Pfizer's Upjohn unit, the Mylan business now operates as part of Viatris Inc., producing oral solid doses, injectables, APIs, and biosimilars across therapeutic areas such as oncology, immunology, diabetes, and chronic disease, with global manufacturing and R&D operations centered in India (Hyderabad and Bangalore).

Product overview

Mylan N.V., now part of Viatris Inc. following the 2020 merger with Pfizer's Upjohn unit, operates as a global generics, complex generics, and biosimilars company. The company provides a wide range of pharmaceutical products across therapeutic areas including zoledronic acid for bone conditions, herpes treatments, G-CSF biosimilars for neutropenia, docusate sodium, transdermal scopolamine, sucralfate API, dalteparin sodium injection, OTC drugs, plaque psoriasis treatments, and acne medicines. Mylan/Viatris operates manufacturing facilities in India producing oral solid doses and injectables, with R&D centers in Hyderabad and Bangalore. The company operates across 165+ countries with approximately 1,400 medicines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zoledronic Acid
  • Herpes Treatment Drugs
  • G-CSF and G-CSF Biosimilars
  • Docusate Sodium
  • Transdermal Scopolamine
  • Sucralfate API
  • Dalteparin Sodium Injection
  • Over The Counter (OTC) Drugs
  • Plaque Psoriasis Treatment
  • Acne Medicine
  • Neurogenic Bladder Infections Treatment

Quantifiable outcome

  • One of the largest global generic pharmaceutical companies with top-tier market position
  • +1 more outcomes

Companies that use Mylan

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Mylan technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Mylan partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and major.

  • Mankind PharmaminorChannel Partner/ Reseller/ Distributor · 30 March 2026Mankind Pharma received a royalty-free, non-exclusive U.S. license to market a generic version of YUPELRI starting April 23, 2039, as part of settlement resolving Hatch-Waxman patent litigation.
  • Biocon LtdmajorStrategic or Co-development Partner · 21 January 2026Mylan Inc. (Viatris) sold its minority stake in Biocon Biologics Ltd to Biocon Ltd for $200 million cash as part of a $400 million two-part transaction, completing the buyback and enabling full integration of Biocon Biologics.
  • Pfizer Inc. (Upjohn)majorStrategic or Co-development Partner · 16 November 2020Mylan N.V. and Pfizer Inc. completed a global transaction combining Mylan with Upjohn (Pfizer's off-patent branded and generic established medicines business) to create Viatris Inc., forming one of the largest global pharmaceutical companies.
  • Natco PharmaminorStrategic or Co-development PartnerNatco/Mylan partnership for GLP-1 drug development in India's weight loss and diabetes-management market competing against branded products.
  • Cipla, Fresenius Kabi, Pfizer, Hetero, AlkemminorOthersPharmaceutical companies including Mylan sought government price increase for chemotherapy drugs Cisplatin and Carboplatin citing rising raw material costs linked to conflict in West Asia.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Mylan competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Mylan social profiles

Digital presence

Mylan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mylan leadership team

Management profile

Number of profiles

Mylan subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Mylan funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mylan M&A and investment

M&A and investment

M&A10 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mylan

What does Mylan do?

Mylan N.V. developed, manufactured, and distributed a broad portfolio of generic, complex generic, specialty, and biosimilar pharmaceutical products. Following the 2020 combination with Pfizer's Upjohn unit, the Mylan business now operates as part of Viatris Inc., producing oral solid doses, injectables, APIs, and biosimilars across therapeutic areas such as oncology, immunology, diabetes, and chronic disease, with global manufacturing and R&D operations centered in India (Hyderabad and Bangalore).

Is Mylan a public or private company?

Mylan is a private company. It is classified as corporate owned and is currently acquired.

When was Mylan founded?

Mylan was founded in 1961. It employs 10,001+ people.

Where is Mylan based?

Mylan is headquartered in Hyderabad, India, in the Asia region.

How does Mylan make money?

Three revenue lines are on record. Generic Pharmaceuticals are the primary driver. The others are complex Generics and Biosimilars and branded Established Medicines.

Does Mylan have an API?

No public API is recorded for Mylan.

What industry is Mylan in?

Mylan's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAC, Sterile Injectable Generics. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooMylan pays Connecticut $8 million after allegedly inflating EpiPen prices by 400%Mylan agreed to pay Connecticut $8 million and distribute 10,000 EpiPens to resolve allegations of inflating EpiPen prices by 400% in 2016. The settlement follows state antitrust claims of pay-for-delay agreements that blocked generic epinephrine auto-injectors. Connecticut officials are continuing antitrust cases against the generic drug industry.YahooTong announces $8M settlement with company that inflated EpiPen pricesConnecticut settled an $8 million lawsuit with Mylan over allegations of illegally inflating EpiPen prices. The company faced criticism in 2016 for a 400% price increase and entered pay-for-delay agreements with competitors. Mylan will provide 10,000 free EpiPens and denies wrongdoing.NDTV ProfitBiocon-Mylan Share Sale: Bernstein Retains 'Underperform', Flags Three Key Risks Ahead — Check Target Price, Potential Upside And MoreBernstein maintained its underperform rating on Biocon Ltd. with a target price of Rs 326, representing a 25.4% downside from the current market price of Rs 437, citing concerns over insufficient revenue growth and balance sheet leverage. The brokerage identified three key risks: investments in Biocon Biologics and Syngene have not generated sufficient returns to support over $1 billion of leverage, policy changes are lowering competitive barriers in the biosimilars business, and the leadership succession plan prioritizes science-led investments over commercial execution. The article also noted Biocon's December 2025 agreement to acquire Mylan's remaining stake in Biocon Biologics for $815 million and the subsequent block sale of Mylan's 5.64% stake in July for approximately Rs 3,680 crore.ScanXTrade Setup for Today: Key Things to Know Before the Opening Bell on July 15, 2026GIFT Nifty futures indicated a flat market opening for India on July 15, 2026, with futures trading at 24,042, down 18.50 points; US markets closed mixed with NASDAQ gaining 0.90% while Asian markets showed strength with Nikkei up 0.86% and Hang Seng rising 0.77%. Crude oil prices increased 1.07% to $80.19 per barrel, gold declined 0.82%, and USD/INR strengthened to 96.19. Institutional flows showed DIIs bought ₹2,927.71 crores against FIIs selling ₹739.69 crores, while Biocon dominated block deals with ₹1,819.34 crores worth of transactions at ₹400 per share involving Mylan's stake sale.BusinessLineMylan exits Biocon with ₹3,679-crore stake sale; Biocon shares jump over 6%Mylan Inc, a part of Viatris, exited its entire 5.64% stake in Biocon Ltd by selling 91.97 crore equity shares for ₹3,679 crore through open market transactions on the BSE and NSE. The shares were sold at an average price of ₹400 per share, with domestic mutual funds, insurance companies, and foreign investors purchasing the stake. Biocon shares jumped over 6% following the announcement, closing at ₹437 on both exchanges.Business News TodayMylan exits Biocon; Morgan Stanley, ICICI Pru MF, Goldman Sachs, Citigroup among 36 investors buy entire 5.64% stakeMylan, a subsidiary of US-based Viatris, exited its entire 5.64 percent stake in Indian biopharmaceutical company Biocon through block deals on July 13, 2026, selling 4.59 crore shares valued at Rs 3,678.68 crore at Rs 400 per share. ICICI Prudential Mutual Fund was the largest buyer among 36 investors, acquiring a 2.26 percent stake for Rs 1,475 crore, with Morgan Stanley, Goldman Sachs, and Citigroup also participating. Biocon shares rallied 6.4 percent to Rs 437.3 on the National Stock Exchange following the transaction.CNBCTV18Stock market closes lower: West Asia tensions, crude spike among 6 key reasonsIndian equity benchmark indices ended lower on July 14, 2026, with the Sensex falling 562 points to 77,055 and the Nifty declining 159 points to 24,052, as escalating West Asia tensions, crude oil price spike, rupee depreciation, HCLTech's mixed Q1 earnings, and banking sector weakness weighed on sentiment. Market breadth was firmly negative with an advance-decline ratio of 1:2, while 34 Nifty stocks ended in the red. Select stocks bucked the trend, with pharma and IT shares outperforming; Biocon surged 7% after Mylan sold its entire 5.6% stake via a block deal, and TCS and Sun Pharma featured among the top Nifty gainers.Analytics InsightBiocon Shares Rise After Mylan Exits Following Rs. 3,676-Crore Stake SaleBiocon Ltd shares surged as much as 7.43% on Tuesday after Mylan completed its complete exit from the Indian biotechnology company through a block deal worth Rs. 3,676 crore, selling its entire 5.64% stake of nearly 9.19 crore shares at around Rs. 400 per share. The stake sale removed a supply overhang that had been pressuring the stock, with investors anticipating additional selling from the large shareholder. Biocon was one of the biggest gainers on the BSE MidCap index, outperforming the Nifty 50 which slipped 0.45% during the session.https://www.outlookbusiness.com/Biocon Shares Hit 52-Week High As Mylan Reportedly Exits Via Block Deal – Outlook BusinessBiocon shares surged over 8% to a 52-week high after Mylan, part of global healthcare company Viatris, exited the company through a block deal selling 9.2 crore shares at approximately ₹400 per share. The transaction was priced at an 8% discount to the previous closing price and was a secondary sale with proceeds going to the selling shareholder. Separately, Biocon's Malaysian subsidiary secured insulin supply contracts worth approximately MYR 225.77 million from Malaysia's Ministry of Health through partner Duopharma Biotech Berhad.Business StandardBiocon rallies after reports of Mylan's exitBiocon's stock surged 7.13% to Rs 440.25 on heavy trading volumes after a large block deal was executed in the counter, with 4.72 crore shares traded on the BSE against a three-month average of 2.49 lakh shares. Media reports indicated that U.S.-based Mylan (owned by Viatris) was looking to sell its entire 5.6% stake in Biocon through block deals worth approximately Rs 3,481 crore, launching at a floor price of Rs 378.50 per share, a 7.9% discount to the prior closing. The transaction would mark Mylan's complete exit from Biocon after a 17-year partnership formed in 2009 to develop and commercialise biosimilars and generic insulin analogues.